Gender and age of matched participants and clinical characteristics of Crohn's disease patients at the time of stool collection
| Controls | Patients | Common to controls and patients | |||||
|---|---|---|---|---|---|---|---|
| Designation Gender/age | Designation Gender/age | Disease location | Disease activity | Diagnosis year | Medication | Surgery | Smoking |
| HC.1 F/39 years | CD.1 F/41 years | L1 | 4 | 1994 | Azathioprine | Small bowel | No |
| HC.2 M/36 years | CD.2 M/37 years | L2 | 2 | 1987 | Azathioprine+Prednisone | Small bowel | Yes |
| HC.3 F/26 years | CD.3 F/29 years | L1+L4 | 5 | 1998 | Azathioprine | No | Yes |
| HC.4 M/27 years | CD.4 M/26 years | L1 | 5 | 2006 | Budesonide | No | No |
| HC.5 F/41 years | CD.5 F/41 years | L3 | 2 | 1990 | Azathioprine | Subtotal colectomy | No |
| HC.6 F/36 years | CD.6 F/38 years | L1 | 5 | 2005 | Mesalazine | No | No |
Disease location according to the Montreal classification: L1 ileum; L2 colon; L3 ileocolon; L4 upper gastrointestinal tract.
Disease activity according to the Harvey–Bradshaw index.20
CD, Crohn's disease; HC, healthy controls.